Vanguard Capital Management’s Castle Biosciences CSTL Stock Holding History
Bought
Maintained
Sold
Other funds holding CSTL
Vanguard Capital Management's CSTL Position: Q3 2026 in Review
Vanguard Capital Management increased its Castle Biosciences (CSTL) stake by 0.93% in Q3 2026, buying an estimated $346K and bringing the position to 1,237,951 shares worth $44M. The position accounts for ﹤0.01% of the portfolio, ranked #1957.
Vanguard Capital Management first reported a position in CSTL in Q1 2026 and has held it in 3 quarters since. 202 funds tracked by Wall St. Rank hold CSTL as of Q3 2026.
- Vanguard Capital Management held 1,237,951 shares of Castle Biosciences worth $44M as of Q3 2026.
- Vanguard Capital Management bought 11,454 Castle Biosciences shares in Q3 2026, an estimated $346K.
- Castle Biosciences made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #1957 holding.
- Vanguard Capital Management first reported a position in Castle Biosciences in Q1 2026 and has held it in 3 quarters since.
- 202 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.